Ascentium Talent (AT), the AI-powered behavioral training platform deployed across more than 40 pharmaceutical companies — including nine of the Top 10 globally by revenue — today announced the appointment of Ywan Karlen as General Manager, EMEA, and Head of Global Strategy & Growth. Karlen will lead European operations from the company's newly incorporated subsidiary, Ascentium Talent GmbH, headquartered in Zug, Switzerland.
The appointment marks a decisive step in AT's global expansion. The platform has been validated across more than 10,000 users and 200,000+ practice sessions, with documented skill improvement of up to 50% across controlled deployments. AT is now bringing that proven capability to European pharmaceutical headquarters concentrated in the Basel-Zurich corridor.
A seasoned bridge between pharma operations and AI
Karlen brings two decades of life sciences and technology leadership spanning Novartis, Veeva Systems, Aktana (now PharmaForceIQ), BASE Life Science, and Deloitte.
- At Novartis Basel HQ, he held global director responsibility for Future Field Engagement Models and International Commercial & Launch Strategy
- At Aktana/PharmaForceIQ, he led EMEA customer success for one of the sector's leading AI-powered commercial intelligence platforms
- At Veeva Systems, he designed CRM architectures across European and Asian markets
Karlen brings both the commercial network and the regulatory literacy — including ISO 27001 and EU AI Act compliance expertise — required to scale a compliance-first AI platform across Europe.
"Ywan's appointment represents exactly the kind of experienced, well-networked operator Europe requires. He speaks the language of pharma commercial excellence, understands the compliance imperatives, and has the credibility to open doors at the largest accounts. We are building Ascentium Talent's European chapter with the right leader at the helm."
— Vic Wu, Founder & CEO, Ascentium Talent
"European pharmaceutical companies are under pressure to demonstrate measurable capability development, not just training completion. AT's platform closes that gap with behavioral science that is published, auditable, and proven at scale. My goal is to establish AT as the standard of excellence for AI-driven sales and medical affairs training across EMEA."
— Ywan Karlen, General Manager, EMEA, Ascentium Talent GmbH
European launch of a proven global platform
Ascentium Talent GmbH was incorporated in Zug in Q2 2026. Switzerland's Basel-Zurich corridor — home to the world's largest pharmaceutical headquarters and a dense ecosystem of regional offices — provides the natural beachhead for European growth.
The Swiss entity operates with independent IP ownership and regional data residency, ensuring GDPR and Swiss FADP compliance, and is developing Swiss-based technology partnerships with public and private local players.
AT's seven AI modules — AI Speech, AI Conversations, AI Listening, MCQ Adaptive Assessment, Key Info Fluency, Open Q&A, and AI Evaluation & Reporting — are already deployed across leading pharmaceutical companies in Asian markets. European rollout commences Q3 2026.
Ascentium Talent is an AI-powered behavioral training platform purpose-built for pharmaceutical commercial and medical teams. The platform uses 2D/3D AI avatars, MUAS® psychometric assessment science, and pharma-grade compliance architecture (MLR guardrails, AE/PC capture, EU AI Act alignment) to deliver measurable HCP engagement capability to field forces. With more than eight years of validated deployments and a client base spanning 40+ pharmaceutical companies across four continents, Ascentium Talent is the behavioral science partner of record for global pharmaceutical commercial excellence.
